| Objective: To study the women with menstrual status in breast cancer pa- tients of different ages, different clinical stages, pathological positive ly- mph node metastasis with or without different between menstrual status and ER, PR, C-erbB-2 positive and negative women between the blood h- ormone levels of the differences between the endocrine treatment of brea- st cancer provide a theoretical basis, as well as pre-determine the recurre- nce and metastasis in patients offer help. Methods: 102 cases of female breast cancer patients measured serum estradiol (estradiol, E2), progesterone (progesterone, PROG), LH (Luteinizing hormone, LH), follicle stimulating hormone (Follicle-stimulating hormone, FSH), prolactin (prolactin, PRL), testosterone (testosterone, TSTO) level. Menstrual status, according to the menstrual pattern which is divided into A group (follicular phase) of 26 cases, B group (ovulation) in 20 cases, C group (luteal phase) three groups of 12 patients, D group (postmen- opausal women)in 44 cases. All subjects were 8-9 in the morning when fasting peripheral venous blood collected. Results: A. Female breast cancer patients of different ages in the same menstrual status of the relationship between hormone levels: follicle less than 45 years of age group of LH, FSH below the more than 45 years old group (p<0.05), ovulation is less than 45 years of age group TSTO higher than 45-year-old group (p<0.05), other levels of the hormone had no significant difference in age. B. Female breast cancer patients of different menstrual status of the comparison between the hormone levels: follicular phase E2 than postmenopausal women (p<0.01), more than 45 years of age group follicular phase LH, FSH higher than the luteal phase group (p <0.01 ), follicular than the luteal phase of PROG and ovulation group (p <0.05). Follicular than the luteal phase of TSTO group (p<0.05). Luteal phase and ovulation group E2, PROG, PRL were higher than postmenopausal women (p<0.05),while the follicular phase, luteal phase and ovulation group LH, FSH were lower than postmenopausal women (p <0.05),Ovulation and the luteal phase and the corresponding hormone levels in the other groups showed no significant difference. C.The same period in female breast cancer patients with different clinical conditions during the comparison of hormone levels: cases are under investigation for clinical stageâ…¡,â…¡patients. Menstrual status in the same clinical stageâ…¡,â…¡patients showed no significant difference in hormone levels. D. Women with menstrual status in breast cancer patients based on pathology results were compared with or without positive lymph nodes: lymph node-positive postmenopausal lymph node-negative group than E2 group (p<0.05), follicular phase shift less than 45 years of age group lymph node metastasis positive group was higher than the negative group LH (p<0.01), others was no significant difference. E. Female breast cancer patients after immunohistochemical results according to ER, PR, C-erbB-2 positive and negative hormone levels were compared between the results see the p values were greater than 0.05, were not statistically different.Conclusion: 1. For a clear endocrine therapy for breast cancer drugs, according to different circumstances with different levels of female hormones to guide the selection of endocrine drugs and dosage may have some value. 2. The current endocrine therapy of breast cancer related to the method is more simple, often to pre-menopausal tamoxifen as first-line drugs, the future of letrozole in postmenopausal often applied as first-line drugs, drug resistance occurs to be treated and then select the line when the second line, third line, four-wire drug treatment. According to women with breast cancer hormone levels in different situations the distribution of different characteristics, in different circumstances to increase or decrease the dose or first-line drugs, or alternatively choose the appropriate combination of second and third line, four-line drug therapy for patients recovery is more likely to beneficial, but also may reduce the occurrence of first-line drug treatment and adverse drug reactions. 3. E2 in postmenopausal women may determine the pathological stage of breast cancer patients to provide some help in judging the prognosis of postmenopausal breast cancer patients may have some significance. LH may be less than 45 years of age to determine the follicular phase of breast cancer pathological stage to provide some help in judging the prognosis of breast cancer patients in this situation may have some significance. 4. Blood sex hormone levels and lesions in the ER, PR, C-erbB-2 positive connection does not exist, yet can not be based female sex hormones in breast cancer patients to guide the blood is suitable for patients with breast cancer endocrine therapy drugs, but can the clinical measurement female breast cancer patients have hormone levels in the results of the comprehensive analysis in order to identify breast cancer cell proliferation, vitality and progress.
|
PDF Full Text Request